Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.

MLA

Zatelli, M. C., et al. “Dopamine Receptor Subtype 2 and Somatostatin Receptor Subtype 5 Expression Influences Somatostatin Analogs Effects on Human Somatotroph Pituitary Adenomas in Vitro.” Journal of Molecular Endocrinology, vol. 35, no. 2, Oct. 2005, pp. 333–41. EBSCOhost, https://doi.org/10.1677/jme.1.01876.

APA

Zatelli, M. C., Piccin, D., Tagliati, F., Bottoni, A., Ambrosio, M. R., Margutti, A., Scanarini, M., Bondanelli, M., Culler, M. D., & degli Uberti, E. C. (2005). Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Journal of Molecular Endocrinology, 35(2), 333–341. https://doi.org/10.1677/jme.1.01876

Chicago

Zatelli, M C, D Piccin, F Tagliati, A Bottoni, M R Ambrosio, A Margutti, M Scanarini, M Bondanelli, M D Culler, and E C degli Uberti. 2005. “Dopamine Receptor Subtype 2 and Somatostatin Receptor Subtype 5 Expression Influences Somatostatin Analogs Effects on Human Somatotroph Pituitary Adenomas in Vitro.” Journal of Molecular Endocrinology 35 (2): 333–41. doi:10.1677/jme.1.01876.